# Mass Balance Study of TQB3616

> **NCT06149611** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 8 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** [14C] TQB3616

## Key facts

- **NCT ID:** NCT06149611
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01
- **Primary completion:** 2024-06
- **Final completion:** 2024-12
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06149611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06149611, "Mass Balance Study of TQB3616". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06149611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*